Skip to content

Ginkgo Bioworks DNA Other Current Liabilities

Other Current Liabilities at other companies

Danaher logo
DanaherDHR
Agilent Technologies logo
Agilent TechnologiesA

Other financials

Income statement

See full
Revenue$19.5M-49.1%
Gross profit$16.4M-52.0%
Operating income-$71.4M+11.9%
Net income-$82.6M+9.2%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$188.7M-46.9%
Total debt$410.7M-5.5%
Total equity$443.2M-31.6%
Total assets$1.0B-20.1%

Cash flow

See full
Operating cash flow-$46.7M+9.4%
CapEx$1.9M-74.6%
Free cash flow-$48.6M+17.8%

Valuation

See full
Market cap$625.16M+24.6%
Enterprise value$847.19M+45.9%
P/S4.4×+2.2×

Profitability

See full
Operating margin-210.7%+7.6pp
Net margin-215.4%+8.3pp
FCF margin-119%-21.2pp

Returns & leverage

See full
Return on equity-55.8%-1.8pp
Debt / equity0.9×+0.3×
Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's other current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ginkgo Bioworks's other current liabilities?
Ginkgo Bioworks (DNA) reported other current liabilities of -$11.6M in Q1 2026.
How has Ginkgo Bioworks's other current liabilities changed year-over-year?
Ginkgo Bioworks's other current liabilities decreased by 230.8% year-over-year, from $8.87M to -$11.6M.
What is the long-term trend for Ginkgo Bioworks's other current liabilities?
Over 3 years (2021 to 2024), Ginkgo Bioworks's other current liabilities has grown at a -3.4% compound annual growth rate (CAGR), from $44.8M to -$40.44M.